CNTN Canton Strategic Holdings Inc
USHealthcareAs of 2026-07-08 16:00
Why CNTN matters now
Canton Strategic Holdings Inc (CNTN) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.32 with -7.20% on the session and $81.4M in market capitalization; recent performance reads 1-month +2.45% and YTD +10.56%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-47.3M, and EPS of $-0.23. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.9%.
The latest indexable market news headline is "Canton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Stetz Gary S. filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.48
P/S
0.00
EV/EBITDA
-1.17
DCF Value
$0.50
FCF Yield
-17.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-36.9%
ROA
-13.8%
ROIC
-8.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-47.3M | $-0.23 |
| Q4 2025 | $0.00 | $-29.4M | $0.85 |
| FY 2025 | $0.00 | $-35.9M | $-1.12 |
| Q3 2025 | $0.00 | $-2.1M | $-0.34 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.43
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.